FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention provides a pharmaceutical composition for intranasal administration containing sumatriptan salt or its physiologically acceptable solvate, alkyl glycoside or saccharide alkyl ester and, optionally, at least one pharmaceutically acceptable excipient, wherein said composition provides a value of Tmax less than 30 minutes after said administration.
EFFECT: invention also provides a method of treating a patient suffering headache or having a tendency to headache, involving intranasal administration of the pharmaceutical composition.
6 cl, 10 ex, 7 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS | 2019 |
|
RU2762725C2 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ARFORMOTEROL AND FLUTICASONE FUROATE | 2013 |
|
RU2678992C2 |
| TRANSMUCOSAL SYSTEM OF DELIVERY OF MEDICAL PRODUCTS | 2004 |
|
RU2342953C2 |
| COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | 2017 |
|
RU2767062C2 |
| COMPOSITIONS AND METHODS OF TREATING OPIOID OVERDOSE | 2017 |
|
RU2769397C2 |
| AXELASTIN AND STEROIDS COMBINATION | 2003 |
|
RU2361593C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING 5HT1-RECEPTOR AGONIST | 2002 |
|
RU2285526C2 |
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2767436C2 |
| ZOLMITRIPTAN-CONTAINING PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2255736C2 |
